CD8A and neoplasm: Two recent Phase II clinical trials of tavo (IL-12) electroporation found that this treatment leads to an increase in NK cell and cDC1-related transcripts in the tumor, an increase in CD8+ T cells in the tumor, and activation of systemic immune responses in treated patients (72, 73).